This online enduring education aims to improve oncologists and advanced practitioners knowledge of testing for overexpression of human epidermal growth factor receptor 2 (HER2) in patients with metastatic non small-cell lung cancer (NSCLC), as well as to improve their clinical skills related to treatment selection/management for HER2-overexpressing NSCLC. As a result of this educational activity, learners should be better able to: 1. Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; 2. Review the efficacy and safety of HER2-directed ADCs for the treatment of HER2-overexpressing metastatic NSCLC; and, 3. Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC. Downloadable slides and podcast are available to learners to use in practice.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/GRK
- Start Date: 2024-12-19 06:00:00
- End Date: 2024-12-19 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 70000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 70000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all